Lexeo Therapeutics, Inc. (LXEO): R&D Expense
$63.80M
Year ended 2025-12-31
$66.64M
Trailing 12 months to 2026-06-30
+9.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $63.80M | -13.9% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $74.09M | +39.5% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $53.13M | +8.1% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $49.16M | n/a | 2024-03-11, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $63.80M | -13.9% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $63.49M | +53.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $38.31M | -72.1% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $108.89M | +18.6% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $133.72M | +18.9% |
Compare LXEO, TECX, IVVD, CHRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗